Moran Kevin Patrick
SEC CIK 1806596 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| VNDA | Vanda Pharmaceuticals Inc. | SVP, CFO, Treas | 411.4K | $8,780 | $884.5K | 18 | 2021-07-28 | 2026-03-02 |
Most active insiders at VNDA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Polymeropoulos Mihael Hristos | Pres, CEO, Dir, COB | — | $1.28M |
| 2 | Moran Kevin Patrick | SVP, CFO, Treas | — | $351.0K |
| 3 | Williams Timothy | SVP, GC | — | $350.9K |
| 4 | Birznieks Gunther | SVP, Business Development | — | $350.9K |
| 5 | Wijkstrom Joakim | SVP, CMO | — | $254.7K |
| 6 | Honore Tage | Dir | — | $240.9K |
| 7 | McGuire Daniel Patrick | SVP, GC, Sec | — | — |
| 8 | Duncan Charles Cliff | Dir | — | — |
| 9 | Mitchell Stephen Ray | Dir | — | — |
| 10 | Ward Anne Sempowski | Dir | — | — |
Transactions 18
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | 2026-03-02 | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treas | S - Sale | $8.27 | -42.4K | 411.4K | -9% | -$351.0K | |
| 2026-02-19 | 2026-02-18 | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treas | A - Grant | $0.00 | +125.0K | 453.8K | +38% | $0 | |
| 2025-03-04 | 2025-03-01 | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treas | F - Tax | $4.76 | -26.9K | 328.8K | -8% | -$128.2K | |
| 2025-02-24 | 2025-02-21 | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treas | P - Purchase | $4.39 | +2,000 | 355.8K | +0.6% | +$8,780 | |
| 2025-02-20 | 2025-02-18 | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treas | A - Grant | $0.00 | +125.0K | 353.8K | +55% | $0 | |
| 2024-07-29 | 2024-07-29 | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treas | S - Sale | $5.92 | -2,251 | 228.8K | -1.0% | -$13.3K | |
| M | 2024-03-06 | 2024-03-04+ | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treas | S - Sale | $4.31 | -14.7K | 231.0K | -6% | -$63.4K |
| 2024-02-21 | 2024-02-16 | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treas | A - Grant | $0.00 | +125.0K | 245.7K | +104% | $0 | |
| M | 2023-08-01 | 2023-07-28 | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treas | S - Sale | $6.31 | -2,212 | 122.5K | -2% | -$14.0K |
| 2023-06-20 | 2023-06-15 | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treas | S - Sale | $6.29 | -16.0K | 122.9K | -12% | -$100.6K | |
| M | 2023-03-06 | 2023-03-02+ | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treas | S - Sale | $6.27 | -13.9K | 138.9K | -9% | -$87.3K |
| D | 2023-02-21 | 2023-02-16 | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treas | A - Grant | $0.00 | +32.7K | 152.9K | +27% | $0 |
| D | 2022-12-07 | 2022-12-06 | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treas | M - OptEx | $3.12 | +7,500 | 125.0K | +6% | +$23.4K |
| D | 2022-12-07 | 2022-12-06 | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treas | S - Sale+OE | $10.61 | -4,792 | 120.2K | -4% | -$50.8K |
| 2022-08-01 | 2022-07-28 | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treas | S - Sale | $10.97 | -2,239 | 117.5K | -2% | -$24.6K | |
| DM | 2022-03-02 | 2022-03-01+ | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treas | S - Sale | $11.25 | -12.3K | 119.7K | -9% | -$138.5K |
| D | 2022-03-02 | 2022-02-28 | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treas | A - Grant | $0.00 | +32.7K | 132.0K | +33% | $0 |
| 2021-07-30 | 2021-07-28 | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treas | S - Sale | $19.24 | -2,130 | 99.3K | -2% | -$41.0K |
Purchase Sale Sale after option exercise All abbreviations